Literature DB >> 23271818

Supplemental oxygen needs during sleep. Who benefits?

Robert L Owens1.   

Abstract

The physiologic changes that occur in ventilation during sleep contribute to nocturnal oxygen desaturation in those with lung disease. Nocturnal supplemental oxygen is often used as therapy, although convincing data exist only for those who are hypoxemic both during sleep and wake. Ongoing trials may help address whether oxygen should be used in those with only desaturation during sleep. If used, oxygen should be dosed as needed, and patients should be monitored for hypercapnia. Because of its prevalence, obstructive sleep apnea may commonly overlap with lung disease in many patients and have important consequences. Patients with overlap syndromes may be good candidates for noninvasive ventilation during sleep.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23271818     DOI: 10.4187/respcare.01988

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  4 in total

1.  Human non-REM sleep and the mean global BOLD signal.

Authors:  Mark P McAvoy; Enzo Tagliazucchi; Helmut Laufs; Marcus E Raichle
Journal:  J Cereb Blood Flow Metab       Date:  2018-08-03       Impact factor: 6.200

Review 2.  Continuous remote monitoring of COPD patients-justification and explanation of the requirements and a survey of the available technologies.

Authors:  Ivan Tomasic; Nikica Tomasic; Roman Trobec; Miroslav Krpan; Tomislav Kelava
Journal:  Med Biol Eng Comput       Date:  2018-03-05       Impact factor: 2.602

3.  Instability of nocturnal parasympathetic nerve function in patients with chronic lung disease with or without nocturnal desaturation.

Authors:  Keisaku Fujimoto; Haruna Yamazaki; Akikazu Uematsu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-09-11

Review 4.  Sleep in Chronic Obstructive Pulmonary Disease: Evidence Gaps and Challenges.

Authors:  Rachel Jen; Yanru Li; Robert L Owens; Atul Malhotra
Journal:  Can Respir J       Date:  2016-06-08       Impact factor: 2.409

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.